PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Strengthening of Mid-size Biopharmaceutical Companies Indicates Strong Potential for Biopharmaceutical Contract Manufacturing - Contract manufacturing of biopharmaceuticals has moved beyond being a function of
Strengthening of Mid-size Biopharmaceutical Companies Indicates Strong Potential for Biopharmaceutical Contract Manufacturing

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/03/17 - Contract manufacturing of biopharmaceuticals has moved beyond being a function of "available capacity" and "cost" to a strategic option offering flexibility, quicker time to market, and lower scale-up costs.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The market will continue to witness double-digit growth as the current demand is largely driven by first-generation products – rh protein therapeutics and monoclonal antibodies (MAbs) targeted for cancer.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), Global Biopharmaceutical Contract Manufacturing Markets, finds that the markets earned revenues of $2.45 billion in 2007and estimates this to grow to $6.48 billion by 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the Global Biopharmaceutical Contract Manufacturing Markets, then send an email to Melina Trevino, Corporate Communications, at melina.trevino[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

"A large number of first-generation biopharmaceutical products maturing and major biopharmaceutical companies are likely to move these out to contract manufacturing organizations (CMOs) and focus on next-generation drugs, which could offer higher revenues and margins," notes Frost & Sullivan Industry Analyst Barath Shankar Subramanian. "The strengthening of mid-size biopharmaceutical companies serves as the engine for a rapidly growing biopharmaceutical pipeline and is a strong signal for future potential that exists in outsourcing manufacturing."

The fact that CMOs are better equipped to handle manufacturing and improve process efficiency and productivity in comparison to small and emerging biopharmaceutical companies will ensure the sustainability of the business in the long term. Contract manufacturing of biopharmaceuticals enables smaller and mid-tier companies to retain greater control over their products rather than out-licensing or selling them to bigger biotechnology or pharmaceutical companies.

"Manufacturing of biopharmaceuticals is a capital-intensive, complex, and highly technical process in comparison to manufacturing of small molecules," says Subramanian. "Investment in captive manufacturing capacity for biopharmaceuticals is a tricky decision for most companies as product development timelines are lengthy and often risky with a high risk of failure."

"Risk-sharing" partnerships and "preferred vendor" models are vital to a sustainable CMO business. Formulation development, consulting services, logistics, packaging, and proprietary technology platforms are other services increasingly being offered by CMOs.

Global Biopharmaceutical Contract Manufacturing Markets is part of the Pharmaceuticals & Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: Global Pharmaceutical Contract Manufacturing Markets, Global CRO Spending Trends, and U.S. Drug Discovery CRO Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting, and Career Best Practices empower clients to create a growth focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.

Global Biopharmaceutical Contract Manufacturing Markets - N2B9

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Strengthening of Mid-size Biopharmaceutical Companies Indicates Strong Potential for Biopharmaceutical Contract Manufacturing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Al Rowaad Advocates & Legal Consultants





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)